{"id":"NCT04623242","sponsor":"Washington University School of Medicine","briefTitle":"Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.","officialTitle":"A Phase II/III Randomized, Double-Blind, Placebo-Controlled, Cognitive Endpoint, Multi-Center Study of Potential Disease Modifying Therapies in Individuals at Risk for and With Dominantly Inherited Alzheimer's Disease","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2012-12","primaryCompletion":"2019-11-22","completion":"2020-03-06","firstPosted":"2020-11-10","resultsPosted":"2022-09-22","lastUpdate":"2022-09-22"},"enrollment":194,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Alzheimers Disease","Dementia","Alzheimers Disease, Familial"],"interventions":[{"type":"DRUG","name":"Gantenerumab","otherNames":["RO4909832"]},{"type":"DRUG","name":"Solanezumab","otherNames":["LY2062430"]},{"type":"DRUG","name":"Matching Placebo (Gantenerumab)","otherNames":[]},{"type":"DRUG","name":"Matching Placebo (Solanezumab)","otherNames":[]}],"arms":[{"label":"Gantenerumab","type":"EXPERIMENTAL"},{"label":"Solanezumab","type":"EXPERIMENTAL"},{"label":"Matching placebo (Gantenerumab)","type":"PLACEBO_COMPARATOR"},{"label":"Matching Placebo (Solanezumab)","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to assess the safety, tolerability, biomarker and cognitive efficacy of investigational products in subjects who are known to have an Alzheimer's disease-causing mutation by determining if treatment with the study drug slows the rate of progression of cognitive impairment and improves disease-related biomarkers.\n\nThis is an analysis study for an MPRP: DIAN-TU-001 Master NCT01760005","primaryOutcome":{"measure":"Assess Cognitive Efficacy in Individuals With Mutations Causing Dominantly Inherited AD as Measured by the DIAN-Multivariate Cognitive Endpoint (DIAN-MCE);","timeFrame":"Baseline through Week 260","effectByArm":[{"arm":"Gantenerumab vs. Mutation Positive Placebo","deltaMin":1.063,"sd":0.059},{"arm":"Solanezumab vs. Mutation Positive Placebo","deltaMin":1.255,"sd":0.061}],"pValues":[{"comp":"OG000","p":null},{"comp":"OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":9,"exclusionCount":9},"locations":{"siteCount":25,"countries":["United States","Australia","Canada","France","Ireland","Puerto Rico","Spain","United Kingdom"]},"refs":{"pmids":["22784036","22672770","27583651","24016464","29761523","27157073","26203303","28703214","30217935","24928124","29250611","38683602","36110925"],"seeAlso":["http://www.dianexr.org/"]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":52},"commonTop":["Nervous system disorders","Injury, poisoning and procedural complications","Infections and infestations","General disorders and administration site conditions","Musculoskeletal and connective tissue disorders"]}}